Acne Vulgaris

Detailed Overview

Acne vulgaris is the most common skin disease, characterized by non-inflammatory lesions (open and closed comedones) and inflammatory lesions (papules, pustules, nodules, and cysts). Androgens drive sebaceous gland hyperplasia and excess sebum, creating a lipid-rich environment conducive to C. acnes overgrowth. The bacterial lipases hydrolyze sebum triglycerides into pro-inflammatory free fatty acids, triggering intense local immune responses. It carries significant psychological morbidity and can lead to permanent scarring if inadequately treated.

Epidemiology & Demographics

Prevalence: Affects up to 85% of adolescents and young adults aged 12-24. Incidence declines with age, though adult-onset acne affects up to 15% of women in their 30s and 40s. Slight male predominance in adolescence (more severe forms), but female predominance in adulthood.

Etiological Mechanism

Multifactorial: driven by androgenic hormones, genetics (high heritability), Cutibacterium acnes colonization, and innate immune system activation. Secondary triggers include medications (corticosteroids, lithium) and endocrine disorders (PCOS).

Primary Causes

Hormonal fluctuations (puberty, menstrual cycle)

Genetics

Polycystic Ovary Syndrome (PCOS)

Medications (steroids, testosterone, lithium)

Occlusive cosmetics

• Family history: Strong genetic predisposition to sebaceous gland sensitivity to androgens.
• High glycemic index diet: Increases IGF-1 and insulin levels, stimulating androgen and sebum production.
• Mechanical friction: Acne mechanica caused by tight clothing, headbands, or chin straps.

1. Microcomedone formation: Hyperproliferation and retention of follicular keratinocytes block the follicular ostium. 2. Sebum overproduction: Androgens stimulate sebocytes to produce excessive sebum. 3. Bacterial colonization: The anaerobic, lipid-rich plugged follicle provides an ideal environment for Cutibacterium acnes. 4. Inflammation: C. acnes activates Toll-like receptor 2 (TLR-2) on monocytes and neutrophils, releasing pro-inflammatory cytokines (IL-1, IL-8, TNF-alpha), leading to follicular rupture and intense dermal inflammation.

Characteristic Clinical Presentation

• Facial lesions: Presence of blackheads, whiteheads, red bumps, and pus-filled spots.
• Pain/Tenderness: Deep nodules and cysts can be exquisitely tender to touch.
• Psychosocial distress: Low self-esteem, anxiety, and depression related to cosmetic appearance.

Physical Examination Signs

• Open comedones (blackheads: melanin oxidized by air)
• Closed comedones (whiteheads)
• Inflammatory papules and pustules (erythematous 2-5mm lesions)
• Nodulocystic lesions (>5mm deep, indurated lesions)
• Post-inflammatory hyperpigmentation or erythema
• Ice-pick, rolling, or boxcar scarring

• Permanent Scarring: Atrophic (ice-pick) or hypertrophic (keloid) scars from deep tissue destruction.
• Post-inflammatory hyperpigmentation: Persistent dark spots lasting months to years after lesions heal.

Diagnostic Criteria & Guidelines

Clinical diagnosis based on the presence of comedones (essential for distinguishing from rosacea/folliculitis) alongside inflammatory lesions in typical seborrheic areas (face, chest, back).

Differential Diagnosis

• Rosacea
• Folliculitis (Malassezia or bacterial)
• Perioral dermatitis
• Hidradenitis suppurativa

Laboratory Tests & Biomarkers

• Total and Free Testosterone: May be elevated if underlying PCOS or adrenal hyperplasia is suspected (usually done in females with hirsutism/irregular menses)
• DHEA-S: Elevated in adrenal hyperandrogenism

Imaging Modalities & Findings

• Pelvic Ultrasound: May show polycystic ovaries if PCOS is the underlying cause.

• Mild
  Few to several comedones, <10 inflammatory lesions, no nodules.
• Moderate
  Several to many comedones, 10-40 inflammatory lesions, prominent on face/trunk.
• Severe
  Numerous comedones and papulopustules, >5 nodules/cysts, extensive scarring.

Second-Line & Adjunctive Therapy

Severe/Nodulocystic: Oral Isotretinoin 0.5-1.0 mg/kg/day for 15-20 weeks (cumulative dose 120-150 mg/kg). Hormonal therapy in females: Spironolactone 50-100 mg/day or combined oral contraceptives (e.g., Ethinyl estradiol/Drospirenone).

Surgical & Procedural Management

Comedone extraction, intralesional triamcinolone acetonide (2.5 mg/mL) injections for large cystic lesions. Laser resurfacing or microneedling for post-acne scarring.

Recommended Lifestyle Changes

• Wash face gently twice daily with a mild, non-comedogenic cleanser.
• Avoid picking, squeezing, or popping lesions to prevent scarring and secondary infection.
• Use only 'oil-free' and 'non-comedogenic' cosmetics and sunscreens.

Patient Counseling & Advice

Inform the patient that topical treatments may cause initial irritation, dryness, and a 'purging' phase where acne temporarily worsens. It takes 6-8 weeks of consistent use to see clinical improvement. Emphasize strict adherence to iPLEDGE protocol (pregnancy prevention) if starting oral isotretinoin, as it is highly teratogenic.

Follow-Up & Monitoring Schedule

Follow up every 4-8 weeks to assess tolerability and efficacy of topical treatments. For isotretinoin, monthly monitoring of pregnancy tests (females), liver function tests (ALT/AST), and lipid panels (triglycerides).

Preventive Strategies

Consistent use of maintenance topical retinoids even after skin clears. Prompt washing after intense sweating. Avoiding occlusive hair products (pomades) near the forehead.

Excellent with proper treatment, though chronicity requires long-term maintenance therapy. Delayed treatment increases the risk of permanent physical scarring and psychosocial sequelae.